RESUMEN
Oligosaccharide and peptide extracts obtained separately from defatted rapeseed meal (DRM) have shown antiproliferative activities on the MCF-7 breast cancer cell line. However, oligosaccharide extracts were not tested on human fibroblasts and have low yields. The objective of the present study was to combine two antiproliferative extracts, the peptides and oligosaccharides, that were obtained independently with commercial enzymes from DRM, allowing improvement of the mass yield and antiproliferative activity. The DRM was solubilized in an alkaline medium to obtain an insoluble meal residue (IMR) and an alkaline extract (RAE). To produce the oligosaccharide extract from IMR, three enzymes and different enzyme/substrate ratios were used. The oligosaccharide extract (molecular weight <30 kDa) recovered with the commercial enzyme. Endogalacturonase showed an 80% inhibition on MCF-7 cells at 20 mg/mL. The combination of this oligosaccharide extract with the peptide extract (obtained with Alkalase 2.4 L from a RAE at 10 mg/mL) inhibited 84.3% of MCF-7 cells proliferation at a concentration of 20 mg/mL, exhibiting no cytotoxic effects on fibroblasts. The mass yield of the extract pool was 27.07% (based on initial DRM). It can be concluded that a mixture of antiproliferative extracts was produced from DRM which was selective against MCF-7 cells.
RESUMEN
Inflammation plays a critical role in the response to and survival from injuries and/or infections. It occurs in two phases: initiation and resolution; however, when these events do not resolve and persist over time, the inflammatory response becomes chronic, prompting diseases that affect several systems and organs, such as the vasculature and the skin. Here, we reviewed inflammation that occurs in selected infectious and sterile pathologies. Thus, the immune processes induced by bacterial sepsis as well as T. cruzi and SARS-CoV-2 infections are shown. In addition, vaccine adjuvants as well as atherosclerosis are revised as examples of sterile-mediated inflammation. An example of the consequences of a lack of inflammation resolution is given through the revision of wound healing and chronic wounds. Then, we revised the resolution of the latter through advanced therapies represented by cell therapy and tissue engineering approaches, showing how they contribute to control chronic inflammation and therefore wound healing. Finally, new pharmacological insights into the management of chronic inflammation addressing the resolution of inflammation based on pro-resolving mediators, such as lipoxin, maresin, and resolvins, examining their biosynthesis, biological properties, and pharmacokinetic and pharmaceuticals limitations, are given. We conclude that resolution pharmacology and advanced therapies are promising tools to restore the inflammation homeostasis.